Formula I TRPV4 Antagonists for Potency and Safety Balance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current TRPV4 inhibitors face challenges with high toxicity, low potency, poor metabolic stability, and safety concerns, limiting their efficacy across various disease indications.
Innovation Solution
Development of compounds that act as TRPV4 antagonists, specifically those of formula I, which demonstrate lower toxicity, improved potency, enhanced metabolic stability, and a higher safety margin, addressing these issues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GSK2798745 is used as a TRPV4 inhibitor, then TRPV4 antagonism is achieved, but toxicity increases and safety margin decreases
Solution Approach 1:
The patent modifies the chemical structure of TRPV4 inhibitors by changing molecular parameters (introducing fluorine atoms, modifying side chains, adjusting molecular weight) to achieve optimal balance between potency and toxicity. Specifically, compounds like 1-((1S,3R)-3-(4-cyanophenyl)-8,8-dimethyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl)methyl-4-fluoro-1H-benzo[d]imidazole-6-carbonitrile exhibit improved safety profiles through these structural parameter optimizations
2Reliability
If TRPV4 inhibitors are developed to achieve high potency, then therapeutic efficacy improves, but metabolic stability deteriorates
Solution Approach 1:
The patent optimizes metabolic stability by modifying molecular parameters including introducing fluorine substitutions (which resist metabolic degradation), adding specific side chains that protect against CYP450 metabolism, and adjusting molecular weight to optimize pharmacokinetic properties. These changes maintain high potency while improving half-life and metabolic stability
3Reliability
If TRPV4 inhibitors are designed with improved potency and safety, then therapeutic benefit increases, but device complexity increases
Solution Approach 1:
The patent achieves improved therapeutic benefit through systematic parameter changes in molecular structure, optimizing substituents and functional groups to balance potency, safety, and complexity. The spiro-piperidine core structure with specific fluorine substitutions and side chains provides an efficient structure-activity relationship that delivers therapeutic effect without excessive structural complexity
Data Source
AI summary
The disclosure provides a compound of formula I:or a salt thereof, wherein R1, R2, R4, L1, L2, and A have any of the values described in the specification, as well as compositions comprising a compound of formula (I). The compounds are useful as TRPV4 antagonists.